ZMYM3
ZMYM3 (Zinc finger MYM-type protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Breast cancer, Head and neck squamous cell carcinoma and 4 more.
Overview
Required for regulation of cell morphology and cytoskeletal organisation.
Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.78, genetic association 0.00, somatic mutation 0.79). IntOGen calls it a driver in 15 cohorts (6 activating, 9 loss-of-function), covering Invasive Breast Carcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Head and Neck Squamous Cell Carcinoma, Lung Adenocarcinoma, Medulloblastoma, Prostate Adenocarcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ZMYM3 (Zinc finger MYM-type protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Breast cancer, Head and neck squamous cell carcinoma and 4 more.
- 1 · What it is
ZMYM3 (Zinc finger MYM-type protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Breast cancer, Head and neck squamous cell carcinoma and 4 more.
- 2 · What goes wrong in cancer
Required for regulation of cell morphology and cytoskeletal organisation. Location: Nucleus (UniProt).
- 3 · How drugs use it
No product in this corpus aims at ZMYM3 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:13054 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q14202 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000147130 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: prostate cancer 0.57 (GraphQL API, CC0)); IntOGen ZMYM3 (driver in 15 cohorts (Act 6, LoF 9); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Required for regulation of cell morphology and cytoskeletal organisation. Location: Nucleus (UniProt). Locus Xq13.1 (HGNC).
- Prostate cancer: Open Targets association 0.57 with prostate cancer (MONDO_0008315); IntOGen driver in 7 cohorts (PRAD, PROSTATE)
- Breast cancer: IntOGen driver in 1 cohort (BRCA)
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
- Chronic lymphocytic leukaemia: IntOGen driver in 2 cohorts (CLLSLL)
- Medulloblastoma: IntOGen driver in 2 cohorts (MBL)
- Non-small-cell lung cancer: IntOGen driver in 1 cohort (LUAD)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 6 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 9 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ZMYM3" OR ABSTRACT:"ZMYM3" OR TITLE:"zinc finger MYM-type containing 3" OR ABSTRACT:"zinc finger MYM-type containing 3" OR TITLE:"Zinc finger MYM-type protein 3" OR ABSTRACT:"Zinc finger MYM-type protein 3" OR TITLE:"ZNF198L2" OR ABSTRACT:"ZNF198L2" OR TITLE:"DXS6673E" OR ABSTRACT:"DXS6673E" OR TITLE:"KIAA0385" OR ABSTRACT:"KIAA0385") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZMYM3, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetKAT6B
Shares Medulloblastoma, Breast cancer (all types), IntOGen, Prostate cancer.
- TargetTRIM33
Shares Medulloblastoma, Breast cancer (all types), IntOGen, Open Targets Platform.
- TargetFOXO3
Shares Medulloblastoma, Breast cancer (all types), IntOGen, Open Targets Platform.
- TargetDDX3X
Shares Medulloblastoma, Breast cancer (all types), IntOGen, Head and neck squamous cell carcinoma.
- TargetTPR
Shares Medulloblastoma, IntOGen, Open Targets Platform.
- TargetFAM174B
Shares Medulloblastoma, IntOGen, Prostate cancer.
- TargetHIP1
Shares Medulloblastoma, Breast cancer (all types), IntOGen, Open Targets Platform.
- TargetHDAC4
Shares Thymoma (WHO types A, AB, B1, B2 and B3), IntOGen, Open Targets Platform.